- C
- N
- O
Calculated reference model · not an experimental or batch-certified structure. Backbone view: 65 of 126 atoms.
Model data & sources
- Heavy atoms only; hydrogens are omitted from the reference display.
- Source-defined atom stereochemistry is checked against the calculated coordinates; no energy-minimum or observed-fold claim is made.
- Reference molecular species only; batch counterions, excipients and material composition are not certified.
- Force-field relaxation reached its iteration limit. This is a geometry-checked reference, not a proven equilibrated or minimum-energy structure.
- Sequence
- YLRIVQCRSVEGSCGF
- Formula
- C78H123N23O23S2
- Method
- Source-graph residue-fragment assembly on idealized backbone / MMFF94s calculated reference conformer (source-edge MMFF reference-length restraints)
- Batch 1 of 2
- KC-AOD-02
- Batch 2 of 2
- KC-AOD-BLK1
AOD-9604
PeptidesPublished formats
- Peptide 5mg
- Dry-Fill Capsule 60ct/250mcg/15mg
What is the difference between these?
- Peptide Vial
- A sealed vial of freeze-dried solid. The stated milligrams are the entire contents of one vial.
- Dry-Fill Capsule
- Capsules filled with the weighed solid. The label gives the amount in each capsule and the number in the bottle.
Supplementary product details from the published catalog, checked 2026-10-07. These reference details do not establish current availability.
Pricing
Pricing and order placement are reserved for reviewed research accounts. Log in or submit an account application to view current product pricing.
Technical Specifications
Batch COA Database ↗Identity fields from the published product record, checked 2026-10-07. Reference information is not a batch identity certificate.
Research Overview
AOD-9604 Research Standard
AOD-9604 (CAS 221231-10-3) is a peptide consisting of the C-terminal fragment of human growth hormone, residues 177–191, with an additional tyrosine residue at the N-terminus. It is also circulated under the name Tyr-hGH fragment 176-191, and both stylings appear in supplier listings — the numbering used here follows the primary analytical characterisation of the molecule.[1]
Mechanism of Action & Research Context
AOD-9604 has no identified receptor. Its documented literature is analytical rather than pharmacological, and the honest framing is that its functional claims are reported rather than established.
-
What is claimed, and by whom. The peptide is reported to mimic the lipolytic properties of growth hormone without the diabetogenic effects. That is the stated rationale for the molecule, and it is worth reading as a design intent rather than a demonstrated result — the source characterising the compound analytically describes it in exactly those reported terms.[1]
-
Six metabolites, one that outlasts the parent. Incubation in serum and urine identified six potential metabolites. Quantification in serum found a single metabolite, the sequence CRSVEGSCG, that is significantly more stable than the other metabolites or the parent compound itself. For method development that inverts the usual assumption: the parent is not necessarily the best analyte.[1]
-
Validated trace detection. A solid-phase extraction method in urine reached a limit of detection of 50 pg/mL with good linearity, precision under 20%, specificity and 62% recovery. Screening for parent and stable metabolite together widens the detection window.[1]
-
Distinct from Fragment 176-191. The unmodified hGH 176-191 fragment is a different peptide with its own CAS number, lacking the N-terminal tyrosine. They are not interchangeable and should not be treated as the same material.
Research Applications
Primary fields of laboratory investigation include:
-
Metabolite identification in serum and urine incubations.[1]
-
Trace-level analytical method development, targeting parent and the stable CRSVEGSCG metabolite together.[1]
-
Solid-phase extraction and LC-MS/MS validation.[1]
-
Comparative work against the unmodified 176-191 fragment to isolate what the N-terminal tyrosine contributes.
Analytical Documentation
Purity and identity vary by manufacturing lot. Kimera Chems does not publish a single fixed purity figure for this item; refer to the batch-specific Certificate of Analysis (COA) issued for the lot received, which reflects third-party analytical testing for that lot.
References
- Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31–38. doi:10.1002/dta.1715
Storage & Handling
Store at controlled room temperature. Keep tightly closed.
Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.
Related Research Compounds
Research Use Only Disclaimer: This product is labeled and sold "For Research Use Only - NOT FOR HUMAN CONSUMPTION." It is not a drug, dietary supplement, food, cosmetic, or medical device, and it is not approved by the FDA or any other regulator for human or veterinary use. It is supplied to approved account holders as a research chemical for laboratory use and must be handled in accordance with applicable law.
Certificates of Analysis
- Batch KC-AODP-01 2 reports
- Batch KC-AOD-BLK1 1 report
- Batch KC-AOD-02 1 report
Currently shipping from batches KC-AOD-02 and KC-AOD-BLK1. The code printed on your label says which one you have.

Compounds That Survive Scrutiny
Research use only. Not for human or veterinary use.